BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuhn L, Strehlau R, Shiau S, Patel F, Shen Y, Technau KG, Burke M, Sherman G, Coovadia A, Aldrovandi GM, Hazra R, Tsai WY, Tiemessen CT, Abrams EJ; LEOPARD Study Team. Early antiretroviral treatment of infants to attain HIV remission. EClinicalMedicine 2020;18:100241. [PMID: 31993578 DOI: 10.1016/j.eclinm.2019.100241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Faye A. Early antiretroviral treatment of infants to attain HIV remission: Not just a matter of timing. EClinicalMedicine 2020;20:100284. [PMID: 32154504 DOI: 10.1016/j.eclinm.2020.100284] [Reference Citation Analysis]
2 Shalekoff S, Loubser S, Dias BDC, Strehlau R, Shiau S, Wang S, He Y, Abrams EJ, Kuhn L, Tiemessen CT. Normalization of B Cell Subsets but Not T Follicular Helper Phenotypes in Infants With Very Early Antiretroviral Treatment. Front Pediatr 2021;9:618191. [PMID: 33996678 DOI: 10.3389/fped.2021.618191] [Reference Citation Analysis]
3 Shiau S, Strehlau R, Shen Y, He Y, Patel F, Burke M, Abrams EJ, Tiemessen CT, Wang S, Kuhn L. Virologic Response to Very Early HIV Treatment in Neonates. J Clin Med 2021;10:2074. [PMID: 34066021 DOI: 10.3390/jcm10102074] [Reference Citation Analysis]
4 Strehlau R, Burke M, van Aswegen T, Kuhn L, Potterton J. Neurodevelopment in early treated HIV-infected infants participating in a developmental stimulation programme compared with controls. Child Care Health Dev 2021;47:154-62. [PMID: 33150965 DOI: 10.1111/cch.12828] [Reference Citation Analysis]
5 Tarancón-Diez L, Rull A, Herrero P, Vazquez-Alejo E, Peraire J, Guillén S, Navarro-Gomez ML, Viladés C, Muñoz-Fernandez MÁ, Vidal F. Early antiretroviral therapy initiation effect on metabolic profile in vertically HIV-1-infected children. J Antimicrob Chemother 2021;76:2993-3001. [PMID: 34463735 DOI: 10.1093/jac/dkab277] [Reference Citation Analysis]
6 Kuhn L, Paximadis M, Da Costa Dias B, Shen Y, Mncube S, Strehlau R, Shiau S, Patel F, Burke M, Technau KG, Sherman G, Loubser S, Abrams EJ, Tiemessen CT; for the LEOPARD study team. Predictors of cell-associated HIV-1 DNA over one year in very early treated infants. Clin Infect Dis 2021:ciab586. [PMID: 34185838 DOI: 10.1093/cid/ciab586] [Reference Citation Analysis]
7 Morris SE, Dziobek-Garrett L, Strehlau R, Schröter J, Shiau S, Anelone AJN, Paximadis M, de Boer RJ, Abrams EJ, Tiemessen CT, Kuhn L, Yates AJ; EPIICAL Consortium and the LEOPARD study team. Quantifying the Dynamics of HIV Decline in Perinatally Infected Neonates on Antiretroviral Therapy. J Acquir Immune Defic Syndr 2020;85:209-18. [PMID: 32576731 DOI: 10.1097/QAI.0000000000002425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zheng L, Tierney C, Bosch RJ. Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations. Curr HIV/AIDS Rep 2021. [PMID: 34213731 DOI: 10.1007/s11904-021-00569-8] [Reference Citation Analysis]
9 Kuhn L. Early Infant Treatment: Still a Long Way to Go to Reach Human Immunodeficiency Virus Remission. Clin Infect Dis 2021;72:394-5. [PMID: 31926001 DOI: 10.1093/cid/ciaa033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Patel F, Shiau S, Strehlau R, Shen Y, Burke M, Paximadis M, Shalekoff S, Schramm D, Technau KG, Sherman GG, Coovadia A, Tiemessen CT, Abrams EJ, Kuhn L. Low Pretreatment Viral Loads in Infants With HIV in an Era of High-maternal Antiretroviral Therapy Coverage. Pediatr Infect Dis J 2021;40:55-9. [PMID: 32925542 DOI: 10.1097/INF.0000000000002897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Ajibola G, Garcia-Broncano P, Maswabi K, Bennett K, Hughes MD, Moyo S, Mohammed T, Jean-Philippe P, Sakoi M, Batlang O, Lockman S, Makhema J, Kuritzkes DR, Lichterfeld M, Shapiro RL. Viral Reservoir in Early-Treated HIV-Infected Children and Markers for Sustained Viral Suppression. Clin Infect Dis 2021:ciab143. [PMID: 33605999 DOI: 10.1093/cid/ciab143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Vieira VA, Adland E, Malone DFG, Martin MP, Groll A, Ansari MA, Garcia-Guerrero MC, Puertas MC, Muenchhoff M, Guash CF, Brander C, Martinez-Picado J, Bamford A, Tudor-Williams G, Ndung'u T, Walker BD, Ramsuran V, Frater J, Jooste P, Peppa D, Carrington M, Goulder PJR. An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathog 2021;17:e1010090. [PMID: 34793581 DOI: 10.1371/journal.ppat.1010090] [Reference Citation Analysis]
13 Ruel TD, Capparelli EV, Tierney C, Nelson BS, Coletti A, Bryson Y, Cotton MF, Spector SA, Mirochnick M, LeBlanc R, Reding C, Zimmer B, Persaud D, Bwakura-Dangarembizi M, Naidoo KL, Hazra R, Jean-Philippe P, Chadwick EG. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV 2021;8:e149-57. [PMID: 33242457 DOI: 10.1016/S2352-3018(20)30274-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Amin O, Powers J, Bricker KM, Chahroudi A. Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure. Front Immunol 2021;12:757400. [PMID: 34745130 DOI: 10.3389/fimmu.2021.757400] [Reference Citation Analysis]
15 Millar JR, Bengu N, Vieira VA, Adland E, Roider J, Muenchhoff M, Fillis R, Sprenger K, Ntlantsana V, Fatti I, Archary M, Groll A, Ismail N, García-Guerrero MC, Matthews PC, Ndung'u T, Puertas MC, Martinez-Picado J, Goulder P. Early initiation of antiretroviral therapy following in utero HIV infection is associated with low viral reservoirs but other factors determine subsequent plasma viral rebound. J Infect Dis 2021:jiab223. [PMID: 33963757 DOI: 10.1093/infdis/jiab223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wang X, Xu H. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Viruses 2021;13:335. [PMID: 33670027 DOI: 10.3390/v13020335] [Reference Citation Analysis]